跳至主要内容
临床试验/NCT05413226
NCT05413226Unknown不适用

Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility

Legend Labz, Inc.2 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2021年9月28日最近更新:
适应症

试验速览

阶段
不适用
入组人数
5
试验地点
2
主要终点
Amount of Sperm in 1 mL of Ejaculate after Celastrol Ingestion

研究概览

简要总结

Five healthy participants with normal sperm counts and motility will ingest increasing doses of celastrol over a period of several days. After each dose ingestion the participants will provide an ejaculate the next day for sperm analysis. The objective is to see if increasing ingestion levels of celastrol will affect the sperm counts and motility of the participants.

详细描述

Experimental Design This will be an escalating dose study to determine the effects of different enteral dosages on sperm motility. Five healthy participants, of any ethnicity, between 18 and 40 years of age will be candidates for the study.

Baseline Days 1- 3 The five participants arrive at the clinic on Baseline Day 1, and will sign Consent Forms after being qualified by the inclusion and exclusion criteria. The participants will provide the first of three "qualifying" sperm samples (a sperm count of ~20 million sperm per milliliter of ejaculate, and sperm motility of ≥ 40% one hour after ejaculate). If the participants initial sample is "normal," then the participants will return to the clinic after three or more days to provide a second sperm sample. Again, if this second sample also meets the sperm count of ~20 million sperm per milliliter of ejaculate, and sperm motility of ≥ 40% one hour after ejaculate, then the participants will return to the clinic for a third time and provide a third and final "qualifying" sperm sample. The average of the "qualifying" sperm counts obtained during the three-day "qualifying period" will be used for the Baseline data, and will be used to compare sperm counts of the participants who ingest Celastrol during the remaining Experimental Days.

Experimental Day 1 All participants that provide three sperm samples that meet the "qualifying" criteria, will then return to the clinic after three or more days and have the participant medical histories taken; receive a physical examination; and have a blood sample taken. The five participants will be instructed to ingest the first dose of Celastrol (6.7 mg). Three hours after ingestion of this dose, the participants will provide a sperm sample.

Experimental Day 2 The participants will return to the clinic three days (or more) after Experimental Day 1. The five participants will be instructed to ingest the second dose of Celastrol (20.1 mg). Three hours after ingestion of this dose, the participants will provide another sperm sample.

Experimental Day 3 The participants will return to the clinic three days (or more) after Experimental Day 2. The five participants will be instructed to ingest the third dose of Celastrol (40.2 mg). Three hours after ingestion of this dose, the participants will provide another sperm sample.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Sequential
主要目的
Basic Science
盲法
None

盲法说明

The participants will be masked to the dose

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Individuals who are between 18 and 40 years of age and who are found to be healthy without any underlying medical conditions that could affect sperm motility, and are not taking any daily medications. This does not exclude patients who take drugs prn.
  • Individuals who have not be involved in other clinical trials during the last 90 days. -

排除标准

  • Individuals who have been involved in any other clinical trial during the last 90 days.
  • Individuals who have sperm counts lower than that considered "normal." i.e. a sperm count of ~20 million sperm per milliliter of ejaculate, and (b) sperm motility of ≥ 40% one hour after ejaculate.
  • Clinically significant cardiac disease including uncontrolled congestive heart failure and unstable angina
  • Individuals on medications that the clinician feels may affect sperm motility and/or otherwise interfere with the results
  • Medications that might interfere with blood chemistry, or CBCs
  • Subjects who are taking daily medications. The use of therapies prn is allowed.
  • Subjects Less than 18 years of age or over 40 years of age
  • Subjects who have taken anabolic steroid or testosterone during the last six months.
  • Subjects with a current history of addictive alcohol or illegal drug abuse (e.g. cocaine, heroin, etc.).
  • The use of marijuana is allowed, but not preferred.
  • Subjects who are taking 5-alpha-reductase inhibitors (finasteride (Propecia®) and dutasteride (Avodart®), or Chemotherapy: -

结局指标

主要结局

Amount of Sperm in 1 mL of Ejaculate after Celastrol Ingestion

时间窗: One Month

Sperm samples will be analyzed independently for number of sperm

Motility of Sperm in 1 mL of Ejaculate after Celastrol Ingestion

时间窗: One Month

Sperm samples will be analyzed independently for sperm motility

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验